Diamyd Medical provides update on Strategic Review

Following the outcome of the DIAGNODE-3 study, the Company’s immediate priority is to complete the close-out of the Phase 3 program in an efficient and responsible manner. Upon completion of this process, the Board intends to focus on evaluating opportunities to deploy the Company’s strong cash position in ways that can maximize long-term shareholder value. The Company will remain open to investments, partnerships, and strategic opportunities both within and outside the healthcare sector. At the same time, the Company will maintain its GMP-certified biomanufacturing facility in Umea